MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414385 | Name: Nifedipine HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nifedipine HCl is a potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.

Chemical Structure

Nifedipine HCl
CAS#60299-11-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 414385

Name: Nifedipine HCl

CAS#: 60299-11-8 (HCl)

Chemical Formula: C17H19ClN2O6

Exact Mass:

Molecular Weight: 382.79

Elemental Analysis: C, 53.34; H, 5.00; Cl, 9.26; N, 7.32; O, 25.08

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
60299-11-8 (HCl) 21829-25-4 (free base)
Synonym
Nifedipine hydrochloride; Nifedipine HCl; Coracten XL
IUPAC/Chemical Name
Dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylate monohydrochloride
InChi Key
ISQGFMPRCDAJRT-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H18N2O6.ClH/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23;/h5-8,15,18H,1-4H3;1H
SMILES Code
O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC=C2[N+]([O-])=O)OC.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 382.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Shekhar S, Gupta N, Kirubakaran R, Pareek P. Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis. BJOG. 2016 Jan;123(1):40-7. doi: 10.1111/1471-0528.13463. Epub 2015 Jun 26. Review. PubMed PMID: 26113232. 2: Toal CB, Meredith PA, Elliott HL. Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: a literature review comparing amlodipine and nifedipine GITS. Blood Press. 2012 Jul;21 Suppl 1:3-10. doi: 10.3109/08037051.2012.690615. Epub 2012 Jul 5. Review. PubMed PMID: 22762301; PubMed Central PMCID: PMC3469239. 3: Derosa G, Maffioli P. Nifedipine and telmisartan for the treatment of hypertension: the TALENT study. Expert Rev Cardiovasc Ther. 2011 Dec;9(12):1499-503. doi: 10.1586/erc.11.155. Review. PubMed PMID: 22103868. 4: Wilcox CB, Nassar N, Roberts CL. Effectiveness of nifedipine tocolysis to facilitate external cephalic version: a systematic review. BJOG. 2011 Mar;118(4):423-8. doi: 10.1111/j.1471-0528.2010.02824.x. Epub 2010 Dec 24. Review. PubMed PMID: 21199292. 5: Conde-Agudelo A, Romero R, Kusanovic JP. Nifedipine in the management of preterm labor: a systematic review and metaanalysis. Am J Obstet Gynecol. 2011 Feb;204(2):134.e1-20. doi: 10.1016/j.ajog.2010.11.038. Review. PubMed PMID: 21284967; PubMed Central PMCID: PMC3437772. 6: Furmaga EM, Glassman PA, Cunningham FE, Good CB. Reducing the Use of Short-acting Nifedipine by Hypertensives Using a Pharmaceutical Database. In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in Patient Safety: From Research to Implementation (Volume 3: Implementation Issues). Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Feb. PubMed PMID: 21249978. 7: Lundy A, Lutfi N, Beckey C. Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension. Vasc Health Risk Manag. 2009;5(1):429-40. Review. PubMed PMID: 19475779; PubMed Central PMCID: PMC2686260. 8: De Souza AR, Amorim MR, Costa AR. [Nifedipine antihypertensive treatment effects in pre-eclampsia]. Acta Med Port. 2008 Jul-Aug;21(4):351-8. Epub 2008 Oct 24. Review. Portuguese. PubMed PMID: 19094810. 9: Sierra C, Coca A. The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension. Expert Rev Cardiovasc Ther. 2008 Sep;6(8):1055-62. doi: 10.1586/14779072.6.8.1055. Review. PubMed PMID: 18793108. 10: Kuwajima I. [Antihypertensive effects of nifedipine and changing for modified-release formula]. Drugs. 2006;66 Spec No 1:7-9. Review. Japanese. Erratum in: Drugs. 2007;67(13):1849. PubMed PMID: 18203344. 11: Komuro I. [Can nifedipine prevent aging of blood vessels?]. Drugs. 2006;66 Spec No 1:34-6. Review. Japanese. Erratum in: Drugs. 2007;67(13):1849. PubMed PMID: 18200779. 12: Horiuchi M. [Anti-inflammatory effect of nifedipine and vasculoprotection]. Drugs. 2006;66 Spec No 1:28-30. Review. Japanese. Erratum in: Drugs. 2007;67(13):1849. PubMed PMID: 18200777. 13: Yoshino G. [J-MIND study: effect of nifedipine on renal function in Japanese hypertensive patients with diabetes mellitus]. Drugs. 2006;66 Spec No 1:22-4. Review. Japanese. Erratum in: Drugs. 2007;67(13):1849. PubMed PMID: 18200775. 14: Hasebe N. [NICE-Combi study: effect of nifedipine in combination with an angiotensin II receptor blocker on BP control and renal protection]. Drugs. 2006;66 Spec No 1:16-8. Review. Japanese. Erratum in: Drugs. 2007;67(13):1849. PubMed PMID: 18200773. 15: Shimokawa H. [ACTION study: efficacy of nifedipine in preventing cardiovascular disease in patients with coronary artery disease]. Drugs. 2006;66 Spec No 1:10-2. Review. Japanese. Erratum in: Drugs. 2007; 67(13):1849. PubMed PMID: 18200771. 16: Kragten JA, Dunselman PH. Nifedipine Gastrointestinal Therapeutic System (GITS) in the treatment of coronary heart disease and hypertension. Expert Rev Cardiovasc Ther. 2007 Jul;5(4):643-53. Review. PubMed PMID: 17605643. 17: Lyndrup J, Lamont RF. The choice of a tocolytic for the treatment of preterm labor: a critical evaluation of nifedipine versus atosiban. Expert Opin Investig Drugs. 2007 Jun;16(6):843-53. Review. PubMed PMID: 17501696. 18: Lamont RF, Khan KS, Beattie B, Cabero Roura L, Di Renzo GC, Dudenhausen JW, Helmer H, Svare J, van Geijn HP; Steering Group of the International Preterm Labour Council. The quality of nifedipine studies used to assess tocolytic efficacy: a systematic review. J Perinat Med. 2005;33(4):287-95. Review. PubMed PMID: 16207113. 19: Yamagishi S, Takeuchi M. Atheroprotective properties of nifedipine. Int J Tissue React. 2005;27(2):63-7. Review. PubMed PMID: 16035650. 20: King JF, Flenady V, Papatsonis D, Dekker G, Carbonne B. Calcium channel blockers for inhibiting preterm labour; a systematic review of the evidence and a protocol for administration of nifedipine. Aust N Z J Obstet Gynaecol. 2003 Jun;43(3):192-8. Review. PubMed PMID: 14712983.